Resolutions of Annual Geneal Meeting - Seite 2

ITEM 7 – The Annual General Meeting re-elected Deloitte Statsautoriseret Revisionspartnerselskab, company registration number 33963556, as the Company’s auditor.

ITEM 8.a – The Annual General Meeting approved to renew authorizations to increase the share capital with and without pre-emptive rights in the Company’s Articles of Association § 17. The aggregate share capital increases with pre-emptive rights shall be subject to a limit of nominally DKK 75,000,000. For share issues without pre-emptive rights, the aggregate share capital increase shall be subject to a limit of nominally DKK 75,000,000. Both authorizations are proposed to apply until the third anniversary of the Annual General Meeting. The two authorizations will be subject to an aggregate limit of nominally DKK 100,000,000.

ITEM 8.b – The Annual General Meeting approved to renew and amend the authorization to issue warrants to employees and members of management in the Company’s Articles of Association § 18. Accordingly, until April 30, 2026, the Board of Directors is authorized to issue warrants, on one or more occasions, entitling the holder(s) to subscribe for up to nominally DKK 14,000,000 of the share capital of the Company (maximum 10,000,000 in 2024 and any remining amount in 2025 - April 30, 2026).

ITEM 8.c – The Chair of the General Meeting, with a right of substitution, was approved to file the resolutions adopted with the Danish Business Authority and to make any such amendments as the Danish Business Authority may require in order to register or approve the resolutions adopted.

Investor Relations

Claus Thestrup, HC Andersen Capital, [phone], [e-mail]

Ashley R. Robinson, LifeSci Advisors, [phone], [e-mail]

About Acute Kidney Injury

Acute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units. For more information about AKI please visit: https://bioporto.com/aki/.

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.